BIOVAIL CORP INTERNATIONAL Form SC 13D/A September 28, 2001

1

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 7)*

Biovail Corporation International ______ (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 09067K106 _____ (CUSIP Number) Eugene Melnyk Biovail Corporation International 2488 Dunwin Drive Mississauga, Ontario L5L1J9 Canada (416) 285-6000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

June 30, 2001
----(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box / /.

Note: An EDGAR version of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

2 SCHEDULE 13D

CUSIP	No. 09067K106			
1	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON			
	Eugene Melnyk			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) / / (b) / /			
3	SEC USE ONLY			
4	SOURCE OF FUNDS PF			
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM: 2(d) or 2(e)			
	N/A 			
6	CITIZENSHIP OR PLACE OF ORGANIZATION			
	Canada			
		7 SOLE VOTING POWER		
		27,388,496		
	NUMBER OF SHARES BENEFICIALLY OWNED BY	8 SHARED VOTING POWER		
		164,996		
	EACH REPORTING	9 SOLE DISPOSITIVE POWER		
PE	PERSON WITH	27,388,496		
	WIIN	10 SHARED DISPOSITIVE POWER		
		164,996		
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	27,388,496			
12	CHECK BOX IF THE	AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / /		
	N/A			
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)			
	20.3%			
14	TYPE OF REPORTING PERSON*			
	IN			

*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7

(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.

2

3

This Amendment No. 7 amends and supplements the statement on Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on March 30, 1994, as amended by Amendment No. 1 thereto filed with the SEC on April 11, 1995, Amendment No. 2 thereto filed with the SEC on September 25, 1996, Amendment No. 3 thereto filed with the SEC on March 11, 1997, Amendment No. 4 thereto filed with the SEC on May 6, 1997, Amendment No. 5 thereto filed with the SEC on January 13, 1998 and Amendment No. 6 thereto filed with the SEC on March 26, 1998 (as so amended, the "Schedule 13D"), with respect to the common stock, no par value (the "Common Stock"), of Biovail Corporation International (the "Company"). Except as amended by this Amendment No. 7, the Schedule 13D, as heretofore filed with the SEC, shall remain in full force and effect.

ITEM 1. SECURITY AND ISSUER.

This amendment relates to the Common Stock of the Company.

ITEM 2. IDENTITY AND BACKGROUND.

This amendment is being filed by Eugene Melnyk, the Chairman of the Board and a director of the Company. The filing of this amendment shall not be construed as an admission that Mr. Melnyk is, for purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended, the beneficial owner of any securities reported on herein except for the securities stated herein to be beneficially owned by Mr. Melnyk.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

There were no acquisitions of beneficial ownership of Common Stock in the past 60 days. See Item 5(c) for a description of sales of Common Stock during the past 60 days.

ITEM 4. PURPOSE OF TRANSACTION.

Mr. Melnyk's acquisition of the securities of the Company was for the purpose of investment. However, the Mr. Melnyk retains his right to acquire shares of Common Stock and to dispose of shares of Common Stock. In determining whether to purchase or dispose of shares of Common Stock, Mr. Melnyk intends to consider and review various factors on a continuous basis, including the Company's financial condition, business and prospects, other developments concerning the Company, the price and availability of shares of Common Stock, other investment and business opportunities available to Mr. Melnyk, and developments with respect to general economic, monetary and stock market conditions.

Except as otherwise described herein, Mr. Melnyk has no plan or proposal with respect to the Company which relates to or would result in any of the matters listed in Items 4(a) - (j) of Schedule 13D. However, in addition to the rights reserved above, the Mr. Melnyk retains his rights to modify his plans with respect to the transactions described in this Item 4, to acquire

3

4

or dispose of securities of the Company and to formulate plans and proposals which could result in the occurrence of any such events, subject to applicable laws and regulations.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

(a) As of July 13, 2001, Mr. Melnyk may be deemed to be the beneficial owner of 27,388,496 shares of Common Stock (including 24,510,900 shares that are owned directly by Mr. Melnyk, 95,100 shares held by the Eugene Melnyk Registered Retirement Savings Plan, 156,496 shares held by Laura Melnyk (Mr. Melnyk's wife), 2,600,000 shares which are subject to options exercisable within 60 days held by Mr. Melnyk, 17,500 shares which are the subject of warrants exercisable within 60 days held by Mr. Melnyk and 8,500 shares which are the subject of warrants exercisable within 60 days held by Laura Melnyk), which constitute in the aggregate 20.8% of the shares of Common Stock outstanding. In addition, Mr. Melnyk owns options to purchase 1,780,000 shares of Common Stock which are not exercisable within 60 days of the date of this amendment. The shareholdings reported herein give effect to the two-for-one splits of the Common Stock in January 2000 and October 2000.

Except as described in the preceding paragraph, Mr. Melnyk does not beneficially own any shares of Common Stock.

- (b) Except as set forth in the next sentence, Mr. Melnyk has the sole power to vote, direct the voting of, dispose of and direct the disposition of the Common Stock beneficially owned by him. Mr. Melnyk shares with Laura Melnyk (his wife) the power to vote, direct the voting of, dispose of and direct the disposition of the Common Stock beneficially held by her.
- (c) The transactions in the Common Stock effected during the past 60 days are set forth on Schedule A.
- (d) Mr. Melnyk has the sole right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock owned by him.
 - (e) Not applicable.
- ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

Not applicable.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

Not applicable.

4

5

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

September 27, 2001

/s/ Eugene Melnyk

Eugene Melnyk

6

Schedule A

5

Date	Price (\$)	Number of Shares (#)
5/9/01 5/10/01	37.30 39.12	15,000 3,000
5/11/01	39.05	7,000
5/18/01	39.08	18,000
5/22/01	40.23	20,000
5/24/01	39.11	15,000
5/31/01	38.75	72,000

Each transaction represents the sale of shares of Common Stock by Mr. Melnyk in open market transactions.